SciELO - Scientific Electronic Library Online

 
vol.93 issue2Do your diagnostic author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Services on Demand

Article

Indicators

  • Have no cited articlesCited by SciELO

Related links

  • On index processCited by Google
  • Have no similar articlesSimilars in SciELO
  • On index processSimilars in Google

Bookmark


Revista argentina de dermatología

On-line version ISSN 1851-300X

Abstract

LORENZETTI, MS  and  RESTIFO, EJ. Biologic therapy of psoriasis: Literature review. Rev. argent. dermatol. [online]. 2012, vol.93, n.2, pp. 38-55. ISSN 1851-300X.

The treatment of moderate to severe psoriasis is difficult, due to the variable clinical response and the adverse events emerging from the conventional systemic treatment and it is generally unsatisfactory to numerous patients. Given that the currently available treatments have a suppressor and not a curative effect on the disease, the adequate signs and symptoms control requires a long-term continued treatment which, in the case of traditional systemic treatments, conveys a high risk of accumulative toxicity (hepatic-metabolic-hematic-renal failure and risk of neoplasia). Phototherapy itself is limited by the fact that, generally, the patient has to visit an institution three times a week; there can be possible 8-MOP toxicity and risk of neoplasia. Biological psoriasis treatments are targeted against lymphocytes surface proteins or cytokines which act on the psoriasis physiopathogenic mechanisms. A bibliographic-like research was conducted to acquire international experience in biological agents, specially focused on etanercept, infliximab and adalimumab. These proved to be effective and to have a relative safety with regards to infectious and neoplastic complications.

Keywords : Biological therapy; Etanercept; Infliximab; Adalimumab; Psoriasis.

        · abstract in Spanish     · text in Spanish